How Much Does Rezdiffra (Resmetirom) Cost in Idaho in 2026?

Idaho Retail and Cash-Pay Pricing for Rezdiffra

The average cash-pay price for Rezdiffra across Idaho retail pharmacies in 2026 is $3,500 per month, matching the manufacturer list price set by Madrigal Pharmaceuticals. This figure applies to the standard once-daily oral tablet regimen at the approved dosing of 80 mg or 100 mg.

Idaho has a relatively concentrated pharmacy market. Boise-area chain pharmacies (CVS, Walgreens, Albertsons) and independent pharmacies in smaller cities like Idaho Falls, Pocatello, and Twin Falls generally price Rezdiffra within a narrow band around $3,500 because the drug is still under patent exclusivity with a single manufacturer. Unlike older generics, there is no pricing variation driven by competing suppliers.

Patients without insurance can expect to pay $42,000 annually at full list price. Some specialty pharmacies may offer modest cash-pay discounts of 3-5%, but these reductions are inconsistent. The Rezdiffra REMS (Risk Evaluation and Mitigation Strategy) does not restrict dispensing to specialty-only channels, so the drug is technically available at any licensed Idaho pharmacy willing to stock it 1.

For context, the MAESTRO-NASH trial (N=966) that supported FDA approval demonstrated that resmetirom 80 mg produced MASH resolution without worsening of fibrosis in 25.9% of patients at 52 weeks versus 9.7% for placebo 2. That efficacy profile makes Rezdiffra the first and, as of May 2026, only FDA-approved pharmacotherapy specifically targeting metabolic dysfunction-associated steatohepatitis (MASH). The lack of therapeutic alternatives gives Madrigal significant pricing power.

Idaho Medicaid Does Not Cover Rezdiffra

Idaho Medicaid does not include Rezdiffra on its preferred drug list and has not issued a coverage policy for resmetirom as of May 2026. Patients enrolled in Idaho Medicaid, including managed care plans administered through Molina Healthcare of Idaho, cannot obtain Rezdiffra through their benefits.

This gap is not unique to Idaho. Most state Medicaid programs have been slow to add Rezdiffra given its cost and the relatively recent FDA approval in March 2024. Idaho's Division of Medicaid typically evaluates new specialty drugs through its Drug Utilization Review (DUR) Board, which meets quarterly. No public DUR meeting agenda through Q2 2026 has listed resmetirom for formulary review.

Idaho Medicaid enrollees with diagnosed MASH and fibrosis stage F2 or F3 currently face limited pharmacotherapy options. Off-label use of pioglitazone (roughly $15-30 per month generic) or vitamin E (800 IU daily, approximately $10-15 per month over the counter) remain the accessible alternatives, though neither carries an FDA indication for MASH. The American Association for the Study of Liver Diseases (AASLD) practice guidance acknowledges both as options for patients who cannot access resmetirom 3.

Patients on Idaho Medicaid who believe they have a clinical need for Rezdiffra can file a prior authorization exception request. Approval under exception is rare for drugs not yet reviewed by the DUR Board, but documenting liver biopsy-confirmed fibrosis stage and failure of lifestyle intervention strengthens any appeal.

Commercial Insurance Coverage in Idaho

Most major commercial insurers operating in Idaho will cover Rezdiffra with prior authorization. Blue Cross of Idaho, PacificSource Health Plans, Regence BlueShield, and SelectHealth each maintain specialty pharmacy formularies that include resmetirom, though tier placement and cost-sharing vary.

Prior authorization criteria across Idaho commercial plans typically require:

• A confirmed diagnosis of MASH (ICD-10 K75.81)
• Liver biopsy or validated noninvasive test (FibroScan, FIB-4, ELF score) documenting fibrosis stage F2 or F3
• Documentation of at least 6 months of lifestyle modification (diet and exercise counseling)
• Prescribing by or in consultation with a hepatologist or gastroenterologist
• Baseline liver function tests (ALT, AST, bilirubin) within 90 days

Patients placed on a specialty tier can expect copays of $150-500 per month before any manufacturer assistance. Some plans apply coinsurance of 25-30% rather than a flat copay, which on a $3,500 drug translates to $875-1,050 out-of-pocket per fill. Idaho does not have a state-level copay cap for specialty drugs, unlike states such as Colorado or Washington.

The step-therapy requirement is the most common barrier. Several Idaho plans require documented trial of vitamin E or pioglitazone before approving Rezdiffra. Dr. Kenneth Cusi, whose research on pioglitazone in NASH helped shape AASLD guidelines, has noted: "Step therapy that delays access to the only approved MASH therapy in patients with progressive fibrosis introduces real clinical risk. Fibrosis stage is the strongest predictor of liver-related mortality" 4.

Employer-sponsored self-funded plans (common among Idaho's larger employers like Micron Technology, Albertsons Companies, and St. Luke's Health System) set their own formulary rules through their pharmacy benefit manager. These plans may be more or less restrictive than fully insured products, and patients should contact their benefits department directly.

How the Madrigal Pharmaceuticals Savings Card Works in Idaho

Madrigal Pharmaceuticals offers the Rezdiffra Savings Card program for commercially insured patients. The card can reduce out-of-pocket costs to as low as $0 per month for eligible patients, with a maximum annual benefit of $13,000 1.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Rezdiffra, reside in the United States, and not be enrolled in any federal or state government healthcare program (Medicare, Medicaid, TRICARE, VA). Idaho residents on employer-sponsored commercial plans or individual marketplace plans (through Your Health Idaho) with non-government funding meet the criteria.

Activation works through either the Madrigal patient support hub (by phone) or at the point of sale. The pharmacy submits the primary insurance claim first, then processes the savings card as a secondary payer to cover remaining copay or coinsurance. Processing typically adds 5-10 minutes to the first fill.

One practical limitation: the $13,000 annual cap. If a patient's plan charges 30% coinsurance on the $3,500 list price ($1,050 per fill), twelve monthly fills total $12,600 in coinsurance, which fits within the cap. But plans that charge higher coinsurance or that do not negotiate a lower contract price with Madrigal may push annual out-of-pocket exposure above $13,000, at which point the patient pays the difference. Patients should calculate their projected annual cost-share before assuming the card covers everything.

Idaho has no state law restricting manufacturer copay assistance programs, and accumulator adjustment programs (where the insurer does not count copay card dollars toward the deductible) are not prohibited under Idaho insurance code. Patients should verify whether their specific plan uses an accumulator or maximizer program, as this can effectively double out-of-pocket spending over the plan year.

Compounded Resmetirom in Idaho: Legal but Limited

Compounded resmetirom is legal in Idaho when prepared by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Idaho follows federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits compounding of FDA-approved drugs when a prescriber determines that a commercially available product does not meet a patient's medical needs 5.

The practical reality is more nuanced. Resmetirom's active pharmaceutical ingredient (API) must be sourced from an FDA-registered supplier, and as of mid-2026, API availability for resmetirom remains extremely limited. Few if any 503A pharmacies in Idaho are actively compounding resmetirom because bulk API supply chains have not matured.

Patients and prescribers considering compounded resmetirom should confirm:

• The pharmacy holds a current Idaho Board of Pharmacy compounding license
• The API is sourced from an FDA-registered facility
• The prescription includes a specific clinical reason for compounding (such as allergy to an inactive ingredient in the branded tablet or need for a dose not commercially available)
• The pharmacy can provide a certificate of analysis for the compounded product

The Idaho Board of Pharmacy regulates 503A compounding under IDAPA 27.01.01. Outsourcing facilities (503B) can ship compounded products into Idaho without patient-specific prescriptions, but no 503B facility has publicly listed resmetirom in its catalog as of this writing.

Cost data for compounded resmetirom in Idaho is not reliably available because so few pharmacies offer it. Some early estimates from 503A pharmacies in other states have suggested pricing of $200-600 per month, but these figures are speculative until stable API sourcing is established.

Telehealth Prescribing of Rezdiffra in Idaho

Idaho permits telehealth prescribing of Rezdiffra with no state-specific restrictions beyond standard prescribing requirements. Idaho Code Section 54-5707 authorizes the practice of medicine via telehealth, including prescribing, when the provider holds an active Idaho medical license or a qualifying Interstate Medical Licensure Compact license.

This means Idaho patients in rural areas (which account for a significant portion of the state's geography) can obtain a Rezdiffra prescription from a hepatologist or primary care provider via video visit. Given that Idaho has only approximately 40-50 practicing gastroenterologists and hepatologists, most concentrated in Boise, Meridian, and Idaho Falls, telehealth access meaningfully expands the eligible prescribing pool.

A telehealth visit can satisfy the initial prescribing requirements, but patients still need documented fibrosis staging. FibroScan (transient elastography) is available at several Idaho facilities including those affiliated with St. Luke's, Saint Alphonsus, and Portneuf Medical Center. The FIB-4 index, calculated from routine blood work (age, AST, ALT, platelet count), can serve as an initial screening tool, though most insurers require FibroScan or biopsy for prior authorization.

The AASLD recommends monitoring ALT and thyroid function tests at baseline, 12 weeks, and periodically thereafter for patients starting resmetirom 3. Lab monitoring is easily coordinated alongside telehealth visits through local Idaho draw sites.

Strategies to Reduce Rezdiffra Costs in Idaho

For Idaho residents facing the full $3,500 monthly cost, several concrete steps can lower out-of-pocket expenses.

Commercially insured patients should activate the Madrigal savings card before the first fill and verify whether their plan applies accumulator adjustment. If the plan uses an accumulator, patients may benefit from timing their deductible spending to align with the savings card maximum.

Uninsured or underinsured patients can apply to the Madrigal Patient Assistance Program, which provides Rezdiffra at no cost to patients meeting income thresholds (typically at or below 400% of the federal poverty level, or $62,400 for an individual in 2026). Application requires income documentation and a signed prescriber attestation.

Medicare Part D enrollees face a different calculus. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, effective since 2025, limits total Rezdiffra costs to $2,000 per year for Medicare patients whose plan includes Rezdiffra on formulary. However, not all Part D plans cover Rezdiffra, and formulary placement varies by plan. The Medicare Plan Finder tool allows Idaho beneficiaries to search by drug name and zip code.

In the MAESTRO-NASH trial, the 100 mg dose produced a fibrosis improvement of at least one stage in 25.9% of patients versus 14.2% for placebo (P<0.001) 2. Dr. Stephen Harrison, principal investigator for MAESTRO-NASH, stated: "Resmetirom is the first therapy to demonstrate both MASH resolution and fibrosis improvement in a registration trial. Cost barriers that prevent eligible patients from accessing this drug represent a missed opportunity to alter disease trajectory before progression to cirrhosis" 2.

Specialty pharmacy comparison can also yield savings. Idaho patients are not required to use a specific specialty pharmacy unless mandated by their insurer. Calling two or three specialty pharmacies (Optum Specialty, CVS Specialty, Accredo) to compare contracted pricing before the first fill is worth the 30 minutes.

Monitoring Costs Beyond the Drug Price

Rezdiffra's FDA label requires liver function monitoring (ALT, AST) and thyroid function testing (TSH, free T4) before initiation and periodically during treatment 1. In Idaho, a basic hepatic function panel runs $15-40 at commercial labs (Quest, Labcorp) and $50-100 at hospital-based labs without insurance. Thyroid panels cost $30-75.

FibroScan for baseline and follow-up fibrosis staging costs $150-400 per session at Idaho imaging centers. Most insurers cover FibroScan with a MASH diagnosis code, but patients may owe a copay or coinsurance.

Total annual monitoring costs for an insured Idaho patient on Rezdiffra typically add $200-600 to the drug cost, depending on visit frequency and plan design. Uninsured patients should budget $400-1,200 annually for labs and imaging on top of the drug price.

The safety profile from MAESTRO-NASH showed diarrhea (26.7% vs. 15.7% placebo) and nausea (18.5% vs. 8.4% placebo) as the most common adverse events, with ALT elevations above 3 times the upper limit of normal occurring in 1.8% of patients on the 100 mg dose 2. Regular lab monitoring catches hepatotoxicity signals early and is non-negotiable during the first year of therapy.